Contact
searchSearch
HMP Global
Poll

Poll: Bone Health During the Pandemic

09/28/2020

Popular Articles

Misti Paudel
Podcast
Misti Paudel, PhD, on Difficult-to-Treat Rheumatoid Arthritis
08/12/2024
Dr Paudel reviews research she and colleagues conducted to validate the EULAR definition of difficult-to-treat rheumatoid arthritis, and differences among patients with difficult-to-treat RA versus those with controlled disease.
Dr Paudel reviews research she and colleagues conducted to validate the EULAR definition of difficult-to-treat rheumatoid arthritis, and differences among patients with difficult-to-treat RA versus those with controlled disease.
Dr Paudel reviews research she...
08/12/2024
Rheumatology & Arthritis
News
Serum Biomarkers Linked With IBD-Associated axSpA
09/23/2024
Jolynn Tumolo
The genetic variant NOD2/CARD15 polymorphism appears related to subclinical intestinal inflammation in patients with axial spondyloarthritis.
The genetic variant NOD2/CARD15 polymorphism appears related to subclinical intestinal inflammation in patients with axial spondyloarthritis.
The genetic variant NOD2/CARD15...
09/23/2024
Rheumatology & Arthritis
News
Ultraprocessed Food Intake and SLE Incidence Among Women
07/12/2024
Jessica Garlewicz
Sugar- and artificially sweetened-beverages were among the key contributors to heightened risk of developing systemic lupus erythematosus.
Sugar- and artificially sweetened-beverages were among the key contributors to heightened risk of developing systemic lupus erythematosus.
Sugar- and artificially...
07/12/2024
Rheumatology & Arthritis
News
Subcutaneous Ustekinumab Cost Rose 84% Under Medicare Part D, Set to Drop Under Negotiated Price Reduction
08/15/2024
Rebecca Mashaw
Coverage changes omitted self-injected therapies from Part B, but new negotiated price will reduce costs 66-67%.
Coverage changes omitted self-injected therapies from Part B, but new negotiated price will reduce costs 66-67%.
Coverage changes omitted...
08/15/2024
Rheumatology & Arthritis
FDA Alert
FDA Approves Bimekizumab for PsA, nr-axSpA and AS
09/23/2024
Rebecca Mashaw
Already approved for plaque psoriasis, bimekizumab is designed to selectively inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F).
Already approved for plaque psoriasis, bimekizumab is designed to selectively inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F).
Already approved for plaque...
09/23/2024
Rheumatology & Arthritis

Partner Spotlight

Axial Involvement in SpA: A Patient-Centered Exploration, Chapter 1
SPONSORED
Axial Involvement in SpA, Chapter 1
04/26/2022
Ethan Craig, MD, MPH, discusses 3 of his patient cases to identify and differentiate axial involvement within the spectrum of SpA.
Ethan Craig, MD, MPH, discusses 3 of his patient cases to identify and differentiate axial involvement within the spectrum of SpA.
Ethan Craig, MD, MPH, discusses...
04/26/2022
Rheumatology & Arthritis

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use